A 100% human milk-based fortifier from Prolacta® Bioscience
Surgifort
Infants post-surgery achieve a
20.9 g/day
growth velocity with reduced
risk of complications
1
Karpen, H. Impact of an Exclusive Human Milk Diet in Neonates with Congenital Gastrointestinal Disorders: Initial Clinical Results. Oral presentation at ISHMSI, Vienna, 2022 available at: https://player.vimeo.com/video/722923273?h=3b58d480a0
Research. Recovery. Results.
Developed by Prolacta® , Surgifort® is the only 100% human milk–based fortifier designed to achieve safe and early post-surgical fortification. Surgifort has been clinically shown to support growth velocity, providing well-tolerated and adequate caloric intake in term infants recovering from surgery.1Karpen, H. Impact of an Exclusive Human Milk Diet in Neonates with Congenital Gastrointestinal Disorders: Initial Clinical Results. Oral presentation at ISHMSI, Vienna, 2022 available at: https://player.vimeo.com/video/722923273?h=3b58d480a0
Improving outcomes with 100% human milk diet
Recently, a clinical trial of an Exclusive Human Milk Diet (EHMD) versus formula and/or human milk fortified with cow-milk based fortifiers was conducted to examine the benefits of human milk-based fortification. Specific results from the study show infants who received early post-surgical fortification with Surgifort as part of an EHMD experienced these benefits:
20.9 g/day
Improved growth velocity1Karpen, H. Impact of an Exclusive Human Milk Diet in Neonates with Congenital Gastrointestinal Disorders: Initial Clinical Results. Oral presentation at ISHMSI, Vienna, 2022 available at: https://player.vimeo.com/video/722923273?h=3b58d480a0
Growth velocity increased 20.9 g/day with the Surgifort - EHMD group vs 17.2 g/day in the cow milk diet group (p= 0.03)
12 days
Time to achieve full enteral feeds reduced by 12 days.1Karpen, H. Impact of an Exclusive Human Milk Diet in Neonates with Congenital Gastrointestinal Disorders: Initial Clinical Results. Oral presentation at ISHMSI, Vienna, 2022 available at: https://player.vimeo.com/video/722923273?h=3b58d480a0
32 days in the Surgifort- EHMD group vs 44 days in the cow milk diet group (p<0.001)
2% vs 7.3%
Lower incidence of NEC. 1Karpen, H. Impact of an Exclusive Human Milk Diet in Neonates with Congenital Gastrointestinal Disorders: Initial Clinical Results. Oral presentation at ISHMSI, Vienna, 2022 available at: https://player.vimeo.com/video/722923273?h=3b58d480a0
2% with the Surgifort - EHMD group vs 7.3% in the cow milk diet group (p=0.08)
Clinician-to-clinician guidance
Clinician-to-clinician guidance
Support with an existing order
Citations
1 Karpen, H. Impact of an Exclusive Human Milk Diet in Neonates with Congenital Gastrointestinal Disorders: Initial Clinical Results. Oral presentation at ISHMSI, Vienna, 2022 available at: https://player.vimeo.com/video/722923273?h=3b58d480a0